leadf
logo-loader
viewSynairgen PLC

Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up.

Britain’s biggest sports retailer - JD Sports (LON:JD) has announced the scrapping of its dividend after reporting a fall in profit and warned of the continued impact of lower footfall in its stores. But the retailer did reveal an above-forecast profit guidance for its full-year as interim sales only slipping by 7% compared to last year.

And staying with retail - the British Retail Consortium’s (BRC) measure of year-on-year growth in retail sales rose to 3.9% in August from 3.2% in July. This marks the biggest increase since May 2018. Experts are putting this down to more UK shoppers out there because foreign holidays are off the agenda for most people.

Synairgen (LON:SNG) is gaining today after revealing positive data from their phase II study on people with chronic obstructive pulmonary disease - there is an in-depth interview with CEO Richard Marsden on the Proactive website right now - with me.

Arix Bioscience PLC (LON:ARIX) saw its shares jump higher this morning after the biotech companies backer revealed that its net asset value improved markedly in the first half of 2020.

And finally Great Western Mining Corporation PLC (LON:GWMO) rose announcing their first gold from the Mineral Jackpot processing operation is imminent.

Quick facts: Synairgen PLC

Price: 167 GBX

AIM:SNG
Market: AIM
Market Cap: £333.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read